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Background
Multiple risk factors are playing role in development of
osteopenia in JIA. One of the most important is inflam-
matory nature of disease. Etanercept induces rapid and
sustained suppression of JIA disease activity and could
have protective effect on bone.
Aim of the study
To assess influence of etanercept on bone mineral density
(BMD) in patients with JIA.
Patients and methods
In prospective study of 37 JIA pts (26 F, 11 M), mean age
16,3 yrs. with polyarthicular course, we have assessed
BMD and bone mineral content (BMC) by dual x-ray
absorptiometry on the lumbar spine (L2–L4) before and
one or two years (in 13 pts) after introduction of etaner-
cept.
Results of osteodentometry assessment (mean value) are
presented on table 1.
After the first year of treatment we have noticed significant
improvement of all ostedensitometric values. Mean value
difference for BMD, compare to baseline was 7,1% (p <
0,001) for Z score 17,76% (p = 0,002), for BMC 13,13%
(p < 0,001) and for BMDvol 5% (p < 0,001). Bone mineral
status continued to increase during the second years of
treatment as well (13 pts) (p < 0,001).
Conclusion
Our results demonstrated efficacy of etanercept, as TNF
blocker, in improving bone mineral status and precluding
of osteoporosis development in children with JIA. This
beneficial effect on bone was demonstrated on the end of
second year of treatment.
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Table 1: 
variables baseline after 1st year
BMD (g/cm2) 0,909 0,965
Z (SD) -1,2 -0,93
BMC (g/cm) 32,68 36,08
BMD vol (g/cm3)* 0,314 0,329